Aclaris Therapeutics, Inc. (ACRS)
NASDAQ · Manufacturing · Pharmaceutical preparations
ACRS price, last 12 months
Key stats
- Previous close
- $5.38
- Open
- $5.39
- Day range
- $5.10 – $5.54
- 52-week range
- $1.74 – $6.60
- Volume
- 1.5M
- Avg volume (20 days)
- 2.7M
- Market cap
- $758.1M
Performance
Technicals and fundamentals
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $758.1M